Polyclonal Antibody to Immune Receptor Expressed On Myeloid Cells 1 (IREM1)
| Code | Size | Price |
|---|
| PAB377Mu02-20ul | 20ul | £86.00 |
Quantity:
| PAB377Mu02-100ul | 100ul | £158.00 |
Quantity:
| PAB377Mu02-200ul | 200ul | £214.00 |
Quantity:
| PAB377Mu02-1ml | 1ml | £488.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Mouse
Applications:
- Immunocytochemistry (ICC)
- Immunohistochemistry (IHC)
- Immunoprecipitation (IP)
- Western Blot (WB)
Further Information
Alternative Names:
CD300f; CD300LF; NKIR; IGSF13; CLM1; CD300 Antigen Like Family Member F; CMRF35-Like Molecule 1; Immunoglobulin superfamily member 13; NK inhibitory receptor
Buffer Formulation:
PBS, pH7.4, containing 0.02% NaN3, 50% glycerol.
Item Name:
Immune Receptor Expressed On Myeloid Cells 1
Source:
Polyclonal antibody preparation
Usage:
Western blotting: 0.2-2ug/mL;1:250-2500
Immunohistochemistry: 5-20ug/mL;1:25-100
Immunocytochemistry: 5-20ug/mL;1:25-100
Optimal working dilutions must be determined by end user.
Immunohistochemistry: 5-20ug/mL;1:25-100
Immunocytochemistry: 5-20ug/mL;1:25-100
Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Immune Receptor Expressed On Myeloid Cells 1 (IREM1) | RPB377Mu02 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||